Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
出版年份 2021 全文链接
标题
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
作者
关键词
Lung cancer, Immune checkpoint inhibitors, Advanced cancer, NSCLC, Biomarker, PD-L1, Prognostic, Total metabolic tumour volume, [18F]FDG PET/CT, Predictive, MTV
出版物
EUROPEAN JOURNAL OF CANCER
Volume 150, Issue -, Pages 99-107
出版商
Elsevier BV
发表日期
2021-04-21
DOI
10.1016/j.ejca.2021.03.020
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
- (2020) Francesco Facchinetti et al. EUROPEAN JOURNAL OF CANCER
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
- (2020) Filippo G. Dall’Olio et al. LUNG CANCER
- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer
- (2018) Alexander L. Chin et al. Clinical Lung Cancer
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
- (2018) Benjamin Houdu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges
- (2017) Etienne Giroux Leprieur et al. EUROPEAN JOURNAL OF CANCER
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
- (2016) Anne Winther-Larsen et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis
- (2014) Hyung-Jun Im et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Inter-observer reproducibility of semi-automatic tumor diameter measurement and volumetric analysis in patients with lung cancer
- (2013) J. Dinkel et al. LUNG CANCER
- Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
- (2012) Hao Zhang et al. International Journal of Computer Assisted Radiology and Surgery
- Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
- (2011) Shengri Liao et al. ACADEMIC RADIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now